Nektar Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NKTR and other ETFs, options, and stocks.

About NKTR

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. 

CEO
Howard W. Robin
CEOHoward W. Robin
Employees
61
Employees61
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
1990
Founded1990
Employees
61
Employees61

NKTR Key Statistics

Market cap
2.05B
Market cap2.05B
Price-Earnings ratio
-7.16
Price-Earnings ratio-7.16
Dividend yield
Dividend yield
Average volume
984.32K
Average volume984.32K
High today
$77.00
High today$77.00
Low today
$70.00
Low today$70.00
Open price
$72.64
Open price$72.64
Volume
1.36M
Volume1.36M
52 Week high
$77.00
52 Week high$77.00
52 Week low
$6.48
52 Week low$6.48

Stock Snapshot

Nektar Therapeutics(NKTR) stock is priced at $72.22, giving the company a market capitalization of 2.05B. It carries a P/E multiple of -7.16.

As of 2026-03-16, Nektar Therapeutics(NKTR) stock has fluctuated between $70.00 and $77.00. The current price stands at $72.22, placing the stock +3.2% above today's low and -6.2% off the high.

Nektar Therapeutics(NKTR) shares are trading with a volume of 1.36M, against a daily average of 984.32K.

During the past year, Nektar Therapeutics(NKTR) stock moved between $6.48 at its lowest and $77.00 at its peak.

During the past year, Nektar Therapeutics(NKTR) stock moved between $6.48 at its lowest and $77.00 at its peak.

NKTR News

Seeking Alpha 3d
Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis

Earnings Call Insights Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis Mar. 13, 2026 3:22 AM ET Nektar The...

Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters Phase III in atopic dermatitis
TipRanks 4d
Nektar reports Q4 EPS ($1.78) vs. 52c last year

Reports Q4 revenue $21.8M vs. $29.2M last year. “2025 was a pivotal year for Nektar (NKTR) as we saw successful and transformative Phase 2 data readouts for rez...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.